Multicentre, Randomized, Parallel, Double-Blind, Vehicle Controlled Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In The Field-Directed Treatment Of Actinic Keratoses Grade I To II (Field Cancerization)

The main purpose of this vehicle-controlled study is to determine the efficacy and safety of a solution of Actikerall® (containing 5-fluorouracil 0.5% and salicylic acid 10.0%) in the field-directed treatment of grade I-II actinic keratosis, when it is applied to the affected area once daily for 12 weeks.
A secondary objective of this study is to evaluate the efficacy of Actikerall® solution on subclinical actinic keratosis lesions in a subset of patients.

开始日期2014-10-31

申办/合作机构

Almirall SA

[+1]

NCT01358851 / Completed临床2期

A Prospective Comparator Controlled Randomized Exploratory Study on the Efficacy of LAS 41005 Compared to Cryotherapy in Subjects With Hyperkeratotic Actinic Keratosis

The aim of this study is to evaluate the efficacy and safety of LAS 41005 compared to cryotherapy in subjects with moderate to severe hyperkeratotic actinic keratosis (punch biopsies).

开始日期2011-04-01

申办/合作机构

Almirall SA

NCT00987246 / Completed临床3期

Study on the Efficacy of LAS41005 Compared to Placebo and to LAS106521 in the Treatment of Actinic Keratosis Grade I to II

The purpose of this study is to investigate the efficacy of LAS41005 in comparison to placebo and to LAS106521 in actinic keratosis (AK).

开始日期2008-06-30

申办/合作机构

Almirall SA

100 项与氟尿嘧啶/水杨酸相关的临床结果

登录后查看更多信息

100 项与氟尿嘧啶/水杨酸相关的转化医学

登录后查看更多信息

100 项与氟尿嘧啶/水杨酸相关的专利（医药）

登录后查看更多信息

项与氟尿嘧啶/水杨酸相关的文献（医药）

2022-04-18·The Journal of dermatological treatment4区 · 医学

Early clinical response to 5-fluorouracil 0.5% and salicylic acid 10% topical solution in the treatment of actinic keratoses of the head: an observational study.

4区 · 医学

Article

作者: Virginia Garofalo ; Francesco Geraci ; Monia Di Prete ; Caterina Lanna ; Flavia Lozzi ; Terenzio Cosio ; Sara Lambiase ; Ruslana Gaeta Schumak ; Cosimo Di Raimondo ; Laura Diluvio ; Luca Bianchi ; Elena Campione

BACKGROUND:

Actinic keratosis is one of the most common dermatological disorders. A new topical solution, constituted by 0.5% 5-fluorouracil and 10% salicylic acid (Actikerall, Almirall) has been introduced in the treatment pipeline of non-hyperkeratotic actinic keratoses of the head and neck.

PATIENTS AND METHODS:

We analyzed in an observational prospective clinical study the short-term treatment effectiveness of 5-fluorouracil and salicylic acid on face and scalp actinic keratoses of grade 1 and 2 of forty patients. Efficacy assessment was performed by clinical dermatological examination, collecting color photographs, calculating AKASI score, and by means of dermoscopy for each target lesion at every visit.

RESULTS:

AKASI score decreased from an initial score of 3.3 to a final score of 0.9. At week 4, we were able to record a complete clearance of 50% of the treated lesions and a partial clearance of 28%. At the end of 12 weeks, 84% of the total lesions showed complete clearance, while 8% had partial clearance.

CONCLUSIONS:

5-fluorouracil and salicylic acid topical solution is effective in the treatment of mild to moderate actinic keratoses. In the future, further studies are needed to evaluate the chance of adjusting drug dosage according to patients' and actinic keratoses features.

2017-07-01·Pest management science1区 · 农林科学

Computational design of novel inhibitors to overcome weed resistance associated with acetohydroxyacid synthase (AHAS) P197L mutant.

1区 · 农林科学

Article

作者: Ren-Yu Qu ; Jing-Fang Yang ; Yu-Chao Liu ; Qiong Chen ; Ge-Fei Hao ; Cong-Wei Niu ; Zhen Xi ; Guang-Fu Yang

BACKGOUND:

Acetohydroxyacid synthase (AHAS; EC 2.2.1.6) is the first common enzyme in the biosynthetic pathway leading to the branched-chain amino acids in plants and a wide range of microorganisms. With the long-term and wide application of AHAS inhibitors, weed resistance is becoming a global problem, which leads to an urgent demand for novel inhibitors to antagonize both wild-type and resistant AHAS.

RESULTS:

Pyrimidinyl salicylic acid derivatives, as one of the main classes of commercial AHAS herbicides, show potential anti-resistant bioactivity to wild-type and P197L mutant. In current work, a series of novel 2-benzoyloxy-6-pyrimidinyl salicylic acid derivatives were designed through fragment-based drug discovery. Fortunately, the newly synthesized compounds showed good inhibitory activity against both wild-type and P197L mutant. Some compounds not only had a lower resistance factor value but also showed excellent inhibitory activity against wild-type AHAS and P197L mutant. Furthermore, greenhouse experiments showed compound 11m displayed almost 100% inhibition against both wild-type and high-resistant Descurainia sophia at a dosage of 150 g a.i. ha^-1 .

CONCLUSION:

The present work indicated that the 2-benzoyloxy-6-pyrimidinyl salicylic acid motif was well worth further optimization. Also, compound 11m could be used as a potential anti-resistant AHAS herbicide, which requires further research. © 2016 Society of Chemical Industry.

2016-11-01·Journal of cutaneous medicine and surgery4区 · 医学

Low-Dose 0.5% 5-Fluorouracil/10% Salicylic Acid Topical Solution in the Treatment of Actinic Keratoses.

4区 · 医学

Review

作者: Pedro Herranz ; Colin Morton ; Thomas Dirschka ; Rosario Rodríguez Azeredo ; Rodrigo Roldán-Marín

BACKGROUND:

Actinic keratosis (AK) lesions have the potential to develop into invasive squamous cell carcinomas (SCCs), and approaches to treatment are evolving to try to reduce the burden of SCC.

OBJECTIVE:

To present the published clinical research surrounding the use of 0.5% 5-fluorouracil with 10% salicylic acid (low-dose 5-FU/SA) for the treatment of hyperkeratotic AKs.

METHOD:

A review of published clinical evidence for low-dose 5-FU/SA for the treatment of AKs. The articles were selected following a MEDLINE database search of the combined terms fluorouracil, salicylic acid and actinic keratosis which represent the peer review publications of clinical studies that primarily investigate the use of Actikerall in AK.

RESULTS:

Combining low-dose 5-FU with keratolytic SA is associated with high rates of histologic clearance, reduction in lesion number/area, and sustained clinical response in clinical study and the clinical practice setting. Low-dose 5-FU/SA has also been evaluated using imaging to detect the progression of subclinical AK lesions through a course of the field-directed treatment.

CONCLUSION:

Low-dose 5-FU/SA is an effective and well-tolerated treatment option licensed for the lesion-directed treatment of mild-to-moderate hyperkeratotic AK lesions.

项与氟尿嘧啶/水杨酸相关的新闻（医药）

2024-01-11

·PRNewswire

Almirall Digital Transformation Strategy Analysis Report 2023: Accelerators, Incubators, and Other Innovation Programs

DUBLIN, Jan. 10, 2024 /PRNewswire/ -- The "Almirall - Digital Transformation Strategies" company profile has been added to ResearchAndMarkets.com's offering. This report provides insights into Almirall's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives. Almirall is a global biopharmaceutical company specializing in dermatology. The company develops and commercializes solutions for the treatment of a variety of dermatological diseases such as acne, atopic dermatitis, actinic keratosis, and psoriasis among others. Some of the company's key products are Ilumetri (for moderate-to-severe plaque psoriasis), Wynora cream (for mild-to-moderate plaque psoriasis), Skilarence (for moderate-to-severe plaque psoriasis), Seysara (for acne), Ciclopoli (for onychomycosis), and Klisyri, Actikerall, and Solaraze (for actinic keratosis). The company also produces medicines for the neurological, gastric, and cardiac diseases. The company's key dermatological products have been used by 324,000 people since their launches. Scope Almirall is leveraging several emerging technologies to quickly discover drugs, drive sales, streamline production, expand market presence and help patients recover quickly. Cloud, AI, and digital therapeutics are among the technologies the company is focusing on. Almirall launched its dermatology digital health accelerator, Digital Garden, in 2020 to support startups that are focused on developing technology-based services and solutions for various dermatological diseases. In 2023, Almirall partnered with NTT Data to accelerate the process of extracting information from medical papers. Reasons to Buy Gain insights into Almirall's technology initiatives. Gain insights into its digital strategies and innovation initiatives. Gain insights into its technology themes under focus. Gain insights into its various technology launches and partnerships. Key Topics Covered: Overview Digital Transformation Strategy Accelerators, Incubators, and Other Innovation Programs Technology Focus Technology Initiatives Partnership Network Map ICT Budget and Contracts Key Executives A selection of companies mentioned in this report includes NTT Data ZeClinics Iktos Clariba For more information about this company profile visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

100 项与氟尿嘧啶/水杨酸相关的药物交易

登录后查看更多信息

研发状态

适应症	最高研发状态	国家/地区	公司
光化性角化病	批准上市	捷克更多	Almirall SA 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01358851 (Pubmed)	临床2期	光化性角化病	66	0.5% 5-fluorouracil with 10% salicylic acid (5-FU/SA)	鏇糧範網廠繭網糧鹽餘(鹽淵構鏇範淵築糧顧網) = 網積憲廠蓋艱鏇鏇糧範窪衊醖糧網淵鏇鹽餘範 (觸鹹網餘餘鑰衊遞選鹹 ) 更多	-	2015-05-01
				0.5% 5-fluorouracil (Cryosurgery)	鏇糧範網廠繭網糧鹽餘(鹽淵構鏇範淵築糧顧網) = 網糧窪選鏇網襯製廠簾窪衊醖糧網淵鏇鹽餘範 (觸鹹網餘餘鑰衊遞選鹹 ) 更多